Macular Degeneration clinical trials
9 active trials name this condition. Describe your situation to see which ones look like a fit.
- Effect of Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation on Skin Carotenoid Concentration: A Six-Month, Placebo-Controlled Crossover Study
- Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
- A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
- NYSCF Scientific Discovery Biobank
- Novel Glaucoma Diagnostics
- Factors in Learning And Plasticity: Macular Degeneration
- Vision Rehabilitation Training With Multimodal Feedback in Central Vision Loss
- Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss
- Quest to Analyze One Thousand Humans Meditating
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Macular Degeneration” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.